EP Patent

EP2692346A1 — An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative

Assigned to AbbVie Bahamas Ltd · Expires 2014-02-05 · 12y expired

What this patent protects

Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

USPTO Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Drugs covered by this patent

Patent Metadata

Patent number
EP2692346A1
Jurisdiction
EP
Classification
—
Expires
2014-02-05
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Bahamas Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.